You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Frazier Healthcare Partners pulls in over $617M for latest life sciences fund
Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption
Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4
Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief
Amid Q1 APAC Fintech Funding Slump, Payment Companies Drove Investments
Frazier Healthcare Partners, or Frazier Management LLC, raised over $617 million for Frazier Life Sciences X LP.
The oversubscribed fund will mainly target therapeutics-focused companies that develop and commercialize biopharmaceuticals.
It will invest in company creation, early-stage venture and late-stage private or public opportunities, with two-thirds of its capital to be allocated in seed and series A financing rounds.